Abstract
Boron-neutron capture therapy (BNCT) is an attractive technique for cancer treatment. As such, α, α-cycloalkyl amino acids containing thiododecaborate ([B12H11](2-)-S-) units were designed and synthesized as novel boron delivery agents for BNCT. In the present study, new thiododecaborate α, α-cycloalkyl amino acids were synthesized, and biological evaluation of the boron compounds as boron carrier for BNCT was carried out.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acids / chemistry
-
Boron Compounds / chemical synthesis*
-
Boron Compounds / pharmacology*
-
Boron Neutron Capture Therapy / instrumentation*
-
Brain Neoplasms / physiopathology
-
Brain Neoplasms / radiotherapy*
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Humans
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / pharmacology*
Substances
-
Amino Acids
-
Boron Compounds
-
Radiopharmaceuticals